165 related articles for article (PubMed ID: 34788006)
1. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
2. Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.
Du K; Li X; Feng F
ACS Appl Bio Mater; 2024 Mar; 7(3):1810-1819. PubMed ID: 38403964
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Li X; Shao F; Sun J; Du K; Sun Y; Feng F
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Du K; Xia Q; Heng H; Feng F
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
[TBL] [Abstract][Full Text] [Related]
5. Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
Wang X; Hu A; Du K; Feng F
ACS Appl Bio Mater; 2021 Nov; 4(11):8004-8012. PubMed ID: 35006781
[TBL] [Abstract][Full Text] [Related]
6. Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy.
Sk UH; Hira SK; Rej A; RoyMahapatra D; Manna PP
ACS Appl Bio Mater; 2021 Mar; 4(3):2628-2638. PubMed ID: 35014379
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Petrenko D; Chubarev V; Syzrantsev N; Ismail N; Merkulov V; Sologova S; Grigorevskikh E; Smolyarchuk E; Alyautdin R
Molecules; 2022 May; 27(11):. PubMed ID: 35684445
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
[TBL] [Abstract][Full Text] [Related]
9. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.
He Y; Yang C; Wang Y; Sacher JR; Sims MM; Pfeffer LM; Miller DD
Bioorg Med Chem; 2022 Jan; 53():116533. PubMed ID: 34863065
[TBL] [Abstract][Full Text] [Related]
10. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
12. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
13. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.
Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D
J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771
[TBL] [Abstract][Full Text] [Related]
15. Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Ward SM; Skinner M; Saha B; Emrick T
Mol Pharm; 2018 Nov; 15(11):5263-5276. PubMed ID: 30354145
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy.
Hwang TW; Kim DH; Kim DB; Jang TW; Kim GH; Moon M; Yoon KA; Choi DE; Park JH; Kim JJ
Int J Mol Med; 2019 Mar; 43(3):1478-1486. PubMed ID: 30664150
[TBL] [Abstract][Full Text] [Related]
19. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
20. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]